Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.33 +1.2%	$8.53	$4.00 ▼ $14.44	$787.13M	0.71	1.18 million shs	683,047 shs
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.74 million shs	N/A
COGT Cogent Biosciences	$7.22 +0.6%	$5.86	$3.72 ▼ $12.61	$817.49M	1.88	1.33 million shs	2.32 million shs
CRDF Cardiff Oncology	$3.51 +11.4%	$3.14	$2.01 ▼ $5.64	$209.56M	1.52	1.19 million shs	3.67 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+1.19%	-2.41%	+23.90%	+9.00%	+127.01%
CMRX Chimerix	0.00%	0.00%	0.00%	+0.23%	+882.74%
COGT Cogent Biosciences	+0.56%	-0.28%	+34.20%	+26.22%	-19.24%
CRDF Cardiff Oncology	+11.43%	+9.69%	+5.09%	+16.61%	+71.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.8758 of 5 stars	3.7	0.0	4.7	2.9	0.8	0.6
CMRX Chimerix	0.6839 of 5 stars	1.0	0.0	4.1	0.6	1.7	0.6
COGT Cogent Biosciences	2.5511 of 5 stars	4.4	1.0	0.0	2.8	0.0	0.6
CRDF Cardiff Oncology	1.6615 of 5 stars	3.4	1.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	371.60% Upside
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
COGT Cogent Biosciences	2.75	Moderate Buy	$14.43	99.84% Upside
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	181.34% Upside

Current Analyst Ratings Breakdown

Latest CRDF, AVXL, COGT, and CMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00
5/20/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/7/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
CRDF Cardiff Oncology	$680K	343.41	N/A	N/A	$1.86 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)

Latest CRDF, AVXL, COGT, and CMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
CMRX Chimerix	N/A	6.33	6.33
COGT Cogent Biosciences	N/A	5.13	5.13
CRDF Cardiff Oncology	N/A	6.22	6.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
CMRX Chimerix	45.42%
COGT Cogent Biosciences	N/A
CRDF Cardiff Oncology	16.29%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
CMRX Chimerix	13.10%
COGT Cogent Biosciences	7.29%
CRDF Cardiff Oncology	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.98 million	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable

CRDF, AVXL, COGT, and CMRX Headlines

Recent News About These Companies

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

June 27, 2025 | seekingalpha.com

Cardiff Oncology, Inc. (CRDF) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Jefferies Financial Group Begins Coverage on Cardiff Oncology (NASDAQ:CRDF)

June 26, 2025 | americanbankingnews.com

Cardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Jefferies Financial Group

June 24, 2025 | marketbeat.com

Cardiff Oncology to share CRDF-004 trial data on July 29

June 19, 2025 | finance.yahoo.com

Cardiff selloff brings attractive entry point, says H.C. Wainwright

June 19, 2025 | finance.yahoo.com

Cardiff Oncology Appoints Roger Sidhu, MD as Chief Medical Officer and Announces Upcoming Clinical Data Update for Onvansertib in mCRC Trial

June 19, 2025 | nasdaq.com

Cardiff Oncology (NASDAQ:CRDF) Given "Outperform" Rating at William Blair

June 18, 2025 | marketbeat.com

Cardiff Oncology Names Roger Sidhu as Medical Chief

June 17, 2025 | marketwatch.com

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

June 17, 2025 | globenewswire.com

Two Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)

June 10, 2025 | marketbeat.com

Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)

June 9, 2025 | marketbeat.com

Yarbrough Capital LLC Makes New $277,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

June 8, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF) and Theravance Biopharma (TBPH)

June 4, 2025 | theglobeandmail.com

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented ...

June 4, 2025 | morningstar.comM

Cardiff Oncology Reports 40% Objective Response Rate in Phase 1b Trial of Onvansertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer

June 4, 2025 | nasdaq.com

Nuveen Asset Management LLC Acquires 248,850 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

June 3, 2025 | marketbeat.com

Millennium Management LLC Buys 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

June 3, 2025 | marketbeat.com

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

June 2, 2025 | globenewswire.com

SA Asks: Which oncology companies are attractive M&A targets?

May 30, 2025 | msn.com

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

May 14, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, AVXL, COGT, and CMRX Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.33 +0.11 (+1.19%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$9.37 +0.04 (+0.43%)

As of 07/1/2025 07:02 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)

As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Cogent Biosciences NASDAQ:COGT

$7.22 +0.04 (+0.56%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$7.13 -0.09 (-1.30%)

As of 04:28 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Cardiff Oncology NASDAQ:CRDF

$3.51 +0.36 (+11.43%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$3.60 +0.09 (+2.45%)

As of 05:59 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time